Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2026-02-20 @ 4:44 PM
Study NCT ID:
NCT04500756
Status:
RECRUITING
Last Update Posted:
2025-04-18
First Post:
2020-06-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Limiting AAA With Metformin (LIMIT) Trial
Sponsor:
Stanford University
Organization:
Study Overview
Official Title:
LIMItIng AAA With meTformin (LIMIT) Trial
Status:
RECRUITING
Status Verified Date:
2025-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LIMIT
Brief Summary:
In this research, the investigators are looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s. AAA is an abnormal enlargement of the aorta, which is the large artery in the abdomen (stomach area). The enlargement of the aorta carries a risk that it will rupture and cause life-threatening bleeding in the abdomen (belly). In this study the investigators hope to learn how metformin is associated with the enlargement or change in size of the AAA in study participants. Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 1R61HL146835-01A1 | NIH | None | https://reporter.nih.gov/quic… | View |
| 4R33HL146835-02 | NIH | None | https://reporter.nih.gov/quic… | View |